Author(s): A, Araujo ; Tavares, Nuno ; Faria, Ana Luísa ; Gomes, Rosa ; Mendonça, Joana Carvalho ; Parente, Bárbara ; Capela, Andreia ; Barata, Fernando ; Macedo, Ana
Date: 2023
Persistent ID: http://hdl.handle.net/10400.16/3006
Origin: Repositório Científico da Unidade Local de Saúde de Santo António (ULSSA)
Subject(s): CINV; chemotherapy; nausea; neoplasms; vomiting
Chemotherapy-induced nausea and vomiting (CINV) negatively impact cancer patients' quality of life and treatment outcomes. This study evaluated the achievement of complete response to CINV prophylaxis during the first five days after chemotherapy in adult outpatient cancer clinics with solid malignant tumours receiving Moderate or Highly Emetogenic Chemotherapy (MEC or HEC) in Portugal. During the study, patients completed three evaluations, and nausea severity and CINV impact on patients' daily life was assessed. A complete response (no emetic episodes, no use of rescue antiemetic medication, and no more than mild nausea) was observed in 72% of the cycles (N = 161) throughout the five days after chemotherapy. Amongst the patient population, 25% classified their CINV episodes as severe. Though more than half of the patients achieved a complete response, suggesting that a therapeutic effort is being made to minimise this side effect, the overall scenario is barely optimistic. Significantly, new CINV-control measures in MEC/HEC patients should be adopted, specifically avoiding the single use of dexamethasone and 5-HT3 and raising awareness of using NK1-RAs. Thus, it is critical to improve CINV prophylactic treatment and implement practical international antiemetic guidelines in Portuguese clinical practice, envisaging the improvement of supportive care for cancer patients.
